Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Colorcon
Johnson and Johnson
Harvard Business School
Merck

Last Updated: May 22, 2022

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Phoxillum Bk 4/2.5 In Plastic Container, and what generic alternatives are available?

Phoxillum Bk 4/2.5 In Plastic Container is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.

The generic ingredient in PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate. There are two hundred and eighty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate profile page.

Summary for PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Drug patent expirations by year for PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Recent Clinical Trials for PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 4

See all PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
A06AD Osmotically acting laxatives
A06A DRUGS FOR CONSTIPATION
A06 DRUGS FOR CONSTIPATION
A Alimentary tract and metabolism
A06AG Enemas
A06A DRUGS FOR CONSTIPATION
A06 DRUGS FOR CONSTIPATION
A Alimentary tract and metabolism
A12AA Calcium
A12A CALCIUM
A12 MINERAL SUPPLEMENTS
A Alimentary tract and metabolism
A12BA Potassium
A12B POTASSIUM
A12 MINERAL SUPPLEMENTS
A Alimentary tract and metabolism
A12CA Sodium
A12C OTHER MINERAL SUPPLEMENTS
A12 MINERAL SUPPLEMENTS
A Alimentary tract and metabolism
A12CC Magnesium
A12C OTHER MINERAL SUPPLEMENTS
A12 MINERAL SUPPLEMENTS
A Alimentary tract and metabolism
B05CB Salt solutions
B05C IRRIGATING SOLUTIONS
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
B05CB Salt solutions
B05C IRRIGATING SOLUTIONS
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
B05XA Electrolyte solutions
B05X I.V. SOLUTION ADDITIVES
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
B05XA Electrolyte solutions
B05X I.V. SOLUTION ADDITIVES
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
B05XA Electrolyte solutions
B05X I.V. SOLUTION ADDITIVES
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
B05XA Electrolyte solutions
B05X I.V. SOLUTION ADDITIVES
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
B05XA Electrolyte solutions
B05X I.V. SOLUTION ADDITIVES
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
B05XA Electrolyte solutions
B05X I.V. SOLUTION ADDITIVES
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
G04BA Acidifiers
G04B UROLOGICALS
G04 UROLOGICALS
G Genito-urinary system and sex hormones
V03AG Drugs for treatment of hypercalcemia
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V Various

US Patents and Regulatory Information for PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare Corp PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate INJECTABLE;INJECTION 207026-001 Jan 13, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
McKesson
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.